Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 17/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | LIG1 | P18858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485257 | 0.90 | PCNA (0.61) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL15500034 | 0.86 | PCNA (0.77) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL5741869 | 0.86 | PCNA (0.62) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL16126006 | 0.85 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.85 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL13949733 | 0.82 | PCNA (0.52) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124433 | 0.82 | PCNA (0.80) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL14485269 | 0.81 | PCNA (0.74) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124470 | 0.81 | PCNA (0.82) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL14485275 | 0.81 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140314665-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | NANOPHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140314665-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | NANOPHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8668926-B1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC | 2014-03-11 | — | — | US | disclosed |
| US-8668926-B1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC | 2014-03-11 | — | — | US | disclosed |
| US-20110142941-A1 | Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof | NANOPHARMACEUTICALS LLC | 2011-06-16 | — | — | US | disclosed |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | ORDWAY RESEARCH INSTITUTE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | ORDWAY RESEARCH INSTITUTE, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314665-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | TSHR, TRHR, THRA | PCNA 3971/4885POLB 4145/4885THRA 3/4885 |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | TSHR, THRA, TRHR | PCNA 4375/4885POLB 4116/4885THRA 2/4885 |
| US-20110142941-A1 | Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof | TSHR, THRA, TRHR | PCNA 4329/4885POLB 4139/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.